A major breakthrough for adults living with rare inherited blood disorders, the U.S. Food and Drug Administration (FDA) has officially approved Agios Pharmaceuticals’ oral drug AQVESME™ (mitapivat) for the treatment of anemia in both alpha- and beta-thalassemia, regardless of whether patients require regular blood transfusions or not.